

William Couet

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5801793/publications.pdf>

Version: 2024-02-01

99
papers

3,973
citations

172457

29
h-index

123424

61
g-index

100
all docs

100
docs citations

100
times ranked

3078
citing authors

#	ARTICLE	IF	CITATIONS
1	A physiologically based pharmacokinetic (PBPK) model exploring the blood-milk barrier in lactating species - A case study with oxytetracycline administered to dairy cows and goats. <i>Food and Chemical Toxicology</i> , 2022, 161, 112848.	3.6	8
2	PKPD Modeling of the Inoculum Effect of <i>Acinetobacter baumannii</i> on Polymyxin B in vivo. <i>Frontiers in Pharmacology</i> , 2022, 13, 842921.	3.5	0
3	Clinical Pharmacokinetics of Daptomycin. <i>Clinical Pharmacokinetics</i> , 2021, 60, 271-281.	3.5	20
4	A new PKPD model to characterize the inoculum effect of <i>Acinetobacter baumannii</i> on polymyxin B in vitro. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, , AAC0178921.	3.2	4
5	Pharmacokinetics of colistin after nebulization or intravenous administration of colistin methanesulphonate (Colimycin [®]) to cystic fibrosis patients. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 421-426.	0.7	5
6	Comparative pharmacokinetics of the three echinocandins in ICU patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 2969-2976.	3.0	7
7	Improved antibacterial efficiency of inhaled thiamphenicol dry powders: Mathematical modelling of in vitro dissolution kinetic and in vitro antibacterial efficacy. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 152, 105435.	4.0	5
8	Sequential Time-Kill, a Simple Experimental Trick To Discriminate between Pharmacokinetics/Pharmacodynamics Models with Distinct Heterogeneous Subpopulations versus Homogenous Population with Adaptive Resistance. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	5
9	Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 117-125.	3.0	17
10	Semimechanistic Pharmacodynamic Modeling of Aztreonam+Avibactam Combination to Understand Its Antimicrobial Activity Against Multidrug-Resistant Gram-Negative Bacteria. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019, 8, 815-824.	2.5	8
11	Pharmacokinetics of Polymyxins in Animals. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1145, 89-103.	1.6	3
12	In vitro evaluation of <i>Pseudomonas aeruginosa</i> chronic lung infection models: Are agar and calcium-alginate beads interchangeable?. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 143, 35-43.	4.3	10
13	Preclinical Pharmacokinetic and Pharmacodynamic Data To Support Cefoxitin Nebulization for the Treatment of <i>Mycobacterium abscessus</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	2
14	Reassessing the dosing of cefoxitin prophylaxis during major abdominal surgery: insights from microdialysis and population pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1975-1983.	3.0	8
15	Pulmonary Pharmacokinetics of Oseltamivir Carboxylate in Rats after Nebulization or Intravenous Administration of Its Prodrug, Oseltamivir Phosphate. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	1
16	Cerebrospinal fluid pharmacokinetics of ceftaroline in neurosurgical patients with an external ventricular drain. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 675-681.	3.0	21
17	Use of leucine to improve aerodynamic properties of ciprofloxacin-loaded maltose microparticles for inhalation. <i>European Journal of Pharmaceutical Research</i> , 2019, 1, 02-11.	1.0	20
18	A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2018, 123, 407-422.	2.5	7

#	ARTICLE	IF	CITATIONS
19	New aerosol formulation to control ciprofloxacin pulmonary concentration. <i>Journal of Controlled Release</i> , 2018, 271, 118-126.	9.9	21
20	Active Mediated Transport of Chloramphenicol and Thiamphenicol in a Calu-3 Lung Epithelial Cell Model. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 1178-1184.	3.3	8
21	Pharmacokinetics of colistin in a 8-year-old child with acute bone infection. <i>Clinical Microbiology and Infection</i> , 2018, 24, 1025-1026.	6.0	4
22	A Population WB-PBPK Model of Colistin and its Prodrug CMS in Pigs: Focus on the Renal Distribution and Excretion. <i>Pharmaceutical Research</i> , 2018, 35, 92.	3.5	10
23	Lack of experimental evidence to support mcr-1 -positive <i>Escherichia coli</i> strain selection during oral administration of colistin at recommended and higher dose given by gavage in weaned piglets. <i>International Journal of Antimicrobial Agents</i> , 2018, 51, 128-131.	2.5	5
24	Advances in experimental and mechanistic computational models to understand pulmonary exposure to inhaled drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 113, 41-52.	4.0	57
25	Pharmacokinetics of intravenous and nebulized gentamicin in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 2830-2837.	3.0	13
26	Microdialysis Study of Aztreonam-Avibactam Distribution in Peritoneal Fluid and Muscle of Rats with or without Experimental Peritonitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
27	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 6. Aminoglycosides. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	5
28	Current Progress Toward a Better Understanding of Drug Disposition Within the Lungs: Summary Proceedings of the First Workshop on Drug Transporters in the Lungs. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2234-2244.	3.3	22
29	Clinical Pharmacokinetics and Pharmacodynamics of Colistin. <i>Clinical Pharmacokinetics</i> , 2017, 56, 1441-1460.	3.5	116
30	A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations. <i>Pharmaceutical Research</i> , 2017, 34, 333-351.	3.5	59
31	Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017, 72, 2607-2612.	3.0	32
32	Distinguishing Antimicrobial Models with Different Resistance Mechanisms via Population Pharmacodynamic Modeling. <i>PLoS Computational Biology</i> , 2016, 12, e1004782.	3.2	50
33	Pulmonary pharmacokinetics of levofloxacin in rats after aerosolization of immediate-release chitosan or sustained-release PLGA microspheres. <i>European Journal of Pharmaceutical Sciences</i> , 2016, 93, 184-191.	4.0	26
34	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats. 4. Aztreonam. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 3196-3198.	3.2	17
35	Microdialysis as a way to measure antibiotics concentration in tissues. <i>Pharmacological Research</i> , 2016, 111, 201-207.	7.1	34
36	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 5. Oseltamivir Carboxylate. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 5085-5087.	3.2	4

#	ARTICLE	IF	CITATIONS
37	Ciprofloxacin-Loaded Inorganic-Organic Composite Microparticles To Treat Bacterial Lung Infection. <i>Molecular Pharmaceutics</i> , 2016, 13, 100-112.	4.6	30
38	Impact of colistin sulfate treatment of broilers on the presence of resistant bacteria and resistance genes in stored or composted manure. <i>Veterinary Microbiology</i> , 2016, 194, 98-106.	1.9	28
39	Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1788-1793.	3.2	38
40	Pulmonary delivery of pyrazinamide-loaded large porous particles. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2015, 94, 241-250.	4.3	33
41	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 3. Tobramycin. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 6646-6647.	3.2	44
42	Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys. <i>Pharmaceutical Research</i> , 2015, 32, 3403-3414.	3.5	18
43	Metronidazole and Hydroxymetronidazole Central Nervous System Distribution: 2. Cerebrospinal Fluid Concentration Measurements in Patients with External Ventricular Drain. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1024-1027.	3.2	15
44	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 2. Colistin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3950-3956.	3.2	55
45	Consistent Global Approach on Reporting of Colistin Doses to Promote Safe and Effective Use. <i>Clinical Infectious Diseases</i> , 2014, 58, 139-141.	5.8	60
46	Metronidazole and Hydroxymetronidazole Central Nervous System Distribution: 1. Microdialysis Assessment of Brain Extracellular Fluid Concentrations in Patients with Acute Brain Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 1019-1023.	3.2	25
47	High-throughput hydrophilic interaction chromatography coupled to tandem mass spectrometry for the optimized quantification of the anti-Gram-negatives antibiotic colistin A/B and its pro-drug colistimethate. <i>Journal of Chromatography A</i> , 2014, 1369, 52-63.	3.7	26
48	Comparison of Intrapulmonary and Systemic Pharmacokinetics of Colistin Methanesulfonate (CMS) and Colistin after Aerosol Delivery and Intravenous Administration of CMS in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7331-7339.	3.2	148
49	New Colistin Population Pharmacokinetic Data in Critically Ill Patients Suggesting an Alternative Loading Dose Rationale. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7324-7330.	3.2	78
50	Passive and active strategies for transdermal delivery using co-encapsulating nanostructured lipid carriers: In vitro vs. in vivo studies. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2014, 86, 133-144.	4.3	91
51	Biopharmaceutical Characterization of Nebulized Antimicrobial Agents in Rats: 1. Ciprofloxacin, Moxifloxacin, and Grepafloxacin. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 3942-3949.	3.2	33
52	Effect of experimentally induced hypovolemia on ertapenem tissue distribution using microdialysis in rats. <i>European Journal of Pharmaceutical Sciences</i> , 2014, 51, 45-50.	4.0	5
53	Microdialysis in Antibiotic Research. <i>AAPS Advances in the Pharmaceutical Sciences Series</i> , 2013, , 103-126.	0.6	1
54	Microdialysis Study of Cefotaxime Cerebral Distribution in Patients with Acute Brain Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2738-2742.	3.2	21

#	ARTICLE	IF	CITATIONS
55	Pharmacokinetics of Daptomycin in a Patient with Severe Renal Failure Not Receiving Dialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 2898-2899.	3.2	4
56	Modeling Approach To Characterize Intraocular Doripenem Pharmacokinetics after Intravenous Administration to Rabbits, with Tentative Extrapolation to Humans. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3531-3534.	3.2	1
57	Colistin Distribution in the Peritoneal Fluid of a Patient with Severe Peritonitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 4035-4036.	3.2	5
58	Colistin pharmacokinetics: the fog is lifting. <i>Clinical Microbiology and Infection</i> , 2012, 18, 30-39.	6.0	97
59	Effect of Tamoxifen on the Pharmacokinetics of Theophylline in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 40-42.	2.4	4
60	Pharmacokinetics of Colistin and Colistimethate Sodium After a Single 80-mg Intravenous Dose of CMS in Young Healthy Volunteers. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 875-879.	4.7	119
61	Convulsions and apnoea in a patient infected with New Delhi metallo-β-lactamase-1 Escherichia coli treated with colistin. <i>Journal of Infection</i> , 2011, 63, 468-470.	3.3	24
62	Comparative Cerebrospinal Fluid Diffusion of Imipenem and Meropenem in Rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 52, 1143-1150.	2.4	7
63	Investigation of oral bioavailability and brain distribution of the Ind(8)-Val conjugate of indinavir in rodents. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 57, 453-458.	2.4	8
64	Aerosol Therapy with Colistin Methanesulfonate: a Biopharmaceutical Issue Illustrated in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3702-3707.	3.2	587
65	Removal of colistin during intermittent haemodialysis in two critically ill patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1836-1837.	3.0	48
66	Pharmacokinetics of Ertapenem following Intravenous and Subcutaneous Infusions in Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 924-926.	3.2	40
67	Relative Contributions of Active Mediated Transport and Passive Diffusion of Fluoroquinolones with Various Lipophilicities in a Calu-3 Lung Epithelial Cell Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 543-545.	3.2	35
68	Assay of Colistin and Colistin Methanesulfonate in Plasma and Urine by Liquid Chromatography-Tandem Mass Spectrometry. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 1941-1948.	3.2	130
69	Nefopam Pharmacokinetics in Patients with End-Stage Renal Disease. <i>Anesthesia and Analgesia</i> , 2010, 111, 1146-1153.	2.2	14
70	Kinetics of Imipenem Distribution into the Peritoneal Fluid of Patients with Severe Peritonitis Studied by Microdialysis. <i>Clinical Pharmacokinetics</i> , 2010, 49, 323-334.	3.5	24
71	Dose-ranging pharmacokinetics of colistin methanesulphonate (CMS) and colistin in rats following single intravenous CMS doses. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 1753-1758.	3.0	41
72	Brain Microdialysis Study of Meropenem in Two Patients with Acute Brain Injury. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3502-3504.	3.2	27

#	ARTICLE	IF	CITATIONS
73	Semimechanistic Pharmacokinetic-Pharmacodynamic Model with Adaptation Development for Time-Kill Experiments of Ciprofloxacin against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 2379-2384.	3.2	20
74	P-Glycoprotein-Mediated Transport of Moxifloxacin in a Calu-3 Lung Epithelial Cell Model. <i>Antimicrobial Agents and Chemotherapy</i> , 2009, 53, 1457-1462.	3.2	55
75	A simple and sensitive liquid chromatography-tandem mass spectrometry assay for the quantification of ertapenem in microdialysate. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 862, 242-245.	2.3	19
76	Application of Basic Pharmacokinetic Concepts to Analysis of Microdialysis Data. <i>Clinical Pharmacokinetics</i> , 2008, 47, 181-189.	3.5	27
77	Microdialysis Study of Imipenem Distribution in the Peritoneal Fluid of Rats with Experimental Acute Pancreatitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 1516-1518.	3.2	6
78	Lung Microdialysis Study of Levofloxacin in Rats following Intravenous Infusion at Steady State. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 3074-3077.	3.2	14
79	Steady-state trough serum and epithelial lining fluid concentrations of teicoplanin 12 mg/kg per day in patients with ventilator-associated pneumonia. <i>Intensive Care Medicine</i> , 2006, 32, 775-779.	8.2	600
80	Microdialysis Study of Imipenem Distribution in the Intraperitoneal Fluid of Rats with or without Experimental Peritonitis. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 34-37.	3.2	12
81	Norfloxacin Blood-Brain Barrier Transport in Rats Is Not Affected by Probenecid Coadministration. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 371-373.	3.2	6
82	Microdialysis Study of Imipenem Distribution in Skeletal Muscle and Lung Extracellular Fluids of <i>Acinetobacter baumannii</i> -Infected Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2006, 50, 2265-2267.	3.2	19
83	Lack of Effect of Experimental Hypovolemia on Imipenem Muscle Distribution in Rats Assessed by Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 4974-4979.	3.2	10
84	Pharmacokinetic Modeling of Free Amoxicillin Concentrations in Rat Muscle Extracellular Fluids Determined by Microdialysis. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 3702-3706.	3.2	17
85	Microdialysis Study of Imipenem Distribution in Skeletal Muscle and Lung Extracellular Fluids of Noninfected Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2005, 49, 2356-2361.	3.2	36
86	Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. <i>British Journal of Pharmacology</i> , 2004, 142, 323-330.	5.4	21
87	Extension of the Isobolographic Approach to Interactions Studies Between More than Two Drugs: Illustration with the Convulsant Interaction between Pefloxacin, Norfloxacin, and Theophylline in Rats. <i>Journal of Pharmaceutical Sciences</i> , 2004, 93, 553-562.	3.3	1
88	Dose ranging pharmacokinetics and brain distribution of norfloxacin using microdialysis in rats. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 2458-2465.	3.3	15
89	Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Norfloxacin in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 1952-1957.	3.2	7
90	Norfloxacin-Induced Electroencephalogram Alteration and Seizures in Rats Are Not Triggered by Enhanced Levels of Intracerebral Glutamate. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3660-3662.	3.2	5

#	ARTICLE	IF	CITATIONS
91	Ignoring pharmacokinetics may lead to isoboles misinterpretation: illustration with the norfloxacin-theophylline convulsant interaction in rats. <i>Pharmaceutical Research</i> , 2002, 19, 209-214.	3.5	34
92	Pharmacokinetic-Pharmacodynamic Modeling of the Electroencephalogram Effect of Imipenem in Healthy Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1682-1687.	3.2	15
93	Pharmacokinetic-Pharmacodynamic Modeling of Electroencephalogram Effect of Imipenem in Rats with Acute Renal Failure. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3607-3609.	3.2	5
94	Pharmacokinetic-pharmacodynamic modelling of the convulsant interaction between norfloxacin and biphenyl acetic acid in rats. <i>British Journal of Pharmacology</i> , 2000, 129, 1609-1616.	5.4	8
95	In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. <i>European Journal of Pharmaceutical Sciences</i> , 2000, 12, 85-93.	4.0	85
96	Pharmacokinetic-Pharmacodynamic Contributions to the Convulsant Activity of Fluoroquinolones in Rats. <i>Antimicrobial Agents and Chemotherapy</i> , 1999, 43, 1511-1515.	3.2	30
97	Antagonistic interaction between the convulsant activities of pefloxacin and its main metabolite norfloxacin in rats. <i>Pharmaceutical Research</i> , 1999, 16, 1894-1897.	3.5	7
98	Development of a new quantitative approach for the isobolographic assessment of the convulsant interaction between pefloxacin and theophylline in rats. <i>Pharmaceutical Research</i> , 1998, 15, 1069-1076.	3.5	14
99	A New Approach for Early Assessment of the Epileptogenic Potential of Quinolones. <i>Antimicrobial Agents and Chemotherapy</i> , 1998, 42, 2756-2758.	3.2	9